Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
1.870
+0.035 (1.91%)
At close: Sep 11, 2026, 4:00 PM EDT
1.840
-0.030 (-1.60%)
After-hours: Sep 11, 2026, 7:57 PM EDT
Tvardi Therapeutics Employees
Tvardi Therapeutics had 12 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,171,917
Market Cap
24.94M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 0 | - |
| Dec 31, 2024 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| BeyondSpring | 44 |
| Jasper Therapeutics | 22 |
| ABVC BioPharma | 19 |
| Atossa Therapeutics | 16 |
| Lantern Pharma | 16 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 10 |
TVRD News
- 4 days ago - Tvardi Therapeutics assumed with a Buy at Lucid Capital - TheFly
- 17 days ago - Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewsWire
- 27 days ago - Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c) - TheFly
- 4 weeks ago - Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 - GlobeNewsWire
- 6 weeks ago - Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109 - TheFly
- 6 weeks ago - Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 - GlobeNewsWire
- 2 months ago - Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data - TheFly